LightTable Secures $22.0M Series

Tensormesh

Tensormesh is an AI inference optimization company that never charges you twice for cached tokens, making AI applications faster and dramatically cheaper to run anywhere. Created on leading open-source frameworks, AI teams building agents and LLM applications deploy in minutes with full observability and granular workload control.

Cypher AI

Enable scientists to create custom software tools on demand with advanced scientific aware AI agent. Instead of endless manual data wrangling or rigid, off-the-shelf software, scientists use Cypher’s AI agent to instantly create and run custom software tools, all without requiring coding skills. Researchers can now process, analyze, and manage data at unprecedented speed, unlocking more time for real discovery and innovation.

Sorce

Applying to jobs should be easier and we're making it a reality

Arc

Arc is the capital management platform for ambitious companies and private investors. Arc serves the innovation economy with intelligent cash management and capital markets solutions, in partnership with leading financial institutions and a proprietary network of private credit funds. Founded in 2021, Arc has headquarters in San Francisco and New York City. It has raised over $180 million of equity and debt capital from investors including Left Lane Capital, NFX, Atalaya, Bain Capital Ventures, Clocktower Technology Ventures, Torch Capital, and Y Combinator, among others. To learn more, visit www.joinarc.com. Arc is a financial technology company, not a bank. For important information about Arc, see our general disclosures: https://www.joinarc.com/general-disclosures

Trellis Bioscience Inc.

Trellis Bioscience is a clinical-stage company focused on discovering and developing native human monoclonal antibodies to treat and prevent drug-resistant, life-threatening infectious diseases. Antibodies are the immune system's most potent natural weapon against disease. Trellis's innovative proprietary technology CellSpot™ overcomes technical obstacles that have long hindered exploiting the full human antibody repertoire. This ideal source of drugs focuses on the selection of elite antibodies that bind highly conserved target epitopes with high affinity. TRL1068 is a native human monoclonal antibody (for intravenous delivery) whose target is a family of bacterial proteins (DNABII) that play a critical role in maintaining the structural integrity of biofilms by anchoring extracellular bacterial DNA (eDNA) from dead bacteria within the biofilm matrix. TRL1068 binds at high affinity (Kd ~50 pM) to a highly conserved epitope found in nearly all medically significant bacteria, including both Gram-positive and Gram-negative species. High affinity binding to DNABII ensures that the protein is eliminated from the body and thus prevents its deposition elsewhere in the body, where it could form biofilm metastases. Because the bacterial target is only exposed to the antibody after the producing bacterial cell is dead, resistance to this novel intervention is expected to be rare. The FDA granted Fast Track, QIDP (qualified infectious disease product), and Orphan Drug designations for TRL1068.